TickerTalks
Browse all tickers →
TickerTalks›$ABCL
ABABCL

AbCellera Biologics Inc.

$ABCL·$2.1B·Biotechnology·Healthcare
$11.48+1.1%YTD+220.8%1Y+183.5%
Mentions · last 7 days
2026-08-22: 50 posts2026-08-23: 33 posts2026-08-24: 61 posts568+8%
Price updated 10h ago·X counts updated 7d ago
ABABCL
$ABCLAbCellera Biologics Inc.
$11.48+1.15%568 posts+8%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $ABCL, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Driven by hypeCooling offAI verdict · as of 2026-08-29

Catching its breath after a run — could pick back up or fade from here.

AbCellera has a real Phase 2 win, a fully-funded $200M raise, and directors buying $1.5M — the run is huge and today's -8% is the first cooling breath.

AbCellera is a Vancouver-based antibody-discovery platform that has now leveraged into its own clinical pipeline — ABCL635 for menopausal symptoms is the lead asset, with Vertex and Jazz partnerships behind it. The stock has more than tripled year to date on real data.

  • The Phase 2 read-out was genuinely strong: ABCL635 delivered an ~83% reduction in moderate-to-severe hot flashes at Week 4 — a differentiated result against the non-hormonal category — and the recent Vertex and Jazz partnerships add commercial validation the platform business has been chasing since the COVID-antibody wave rolled off.
  • The insider-buying pattern is unusually clean: three directors and one officer made open-market P-Purchases in August totaling ~$1.55M — Hayden bought twice (~$1.05M combined), Booth $384K, Montalbano $110K — with zero insider sales in the window; that's a real conviction signal at these levels, not routine 10b5-1 optics.
  • The dilution just happened cleanly: the August 13 oversubscribed $200M offering (17.4M common shares plus 3.1M pre-funded warrants) was placed into strength at ~$10 — the runway is now years, not months, and the market absorbed the paper without a crack.

The setup is a real biotech re-rating cooling after a +125% move — today's -8.5% drop is profit-taking against 130% above the 200-day, not a thesis break. The November 5 print won't move the tape (revenue is still tiny) but ABCL635 Phase 3 timing color and Vertex/Jazz milestone updates would; a broader biotech-sector selloff or a P&L that doesn't show ABCL635 progress in commentary would extend the cooling.

Agrees with X sentimentThe near-euphoric X read on the ABCL635 Phase 2 (~83% reduction in moderate-to-severe hot flashes at Week 4), the ~$1.55M cluster of August insider buys with zero sales, the fully-placed $200M offering, and the Vertex/Jazz partnerships is factually consistent — the bull case is anchored on real data. The minority "bearish 4H divergence, take profits after 128%+" caution is fair against a stock 130% above its 200-day.

What to watch: ABCL635 Phase 3 timing and design updates, Vertex/Jazz partnership milestone disclosures, and the November 5 quarterly for commentary. Another cluster of open-market director buys would extend the setup; a broader biotech selloff or a P&L that doesn't show ABCL635 progress in commentary extends the cooling.

On the calendar: 2026-11-05 — Q3 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment117 posts analyzed · as of 2026-08-31

Overwhelmingly bullish, verging on euphoric. Longs cite a 350%+ run off Wave 2 lows fueled by ABCL635 Phase 2 data, a completed $200M offering, the Vertex collaboration, and repeated insider buys near 52-week highs. Carl Hansen's line about the "best-looking pipeline for any company below US$20-billion" in market cap by 2027 gets passed around; several posters call it a multi-bagger they refuse to trim. A small short camp is fading the rip toward single digits.

Read the AI verdict + X sentiment for $ABCL

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

AI-powered antibody discovery platform that partners with pharma to find therapeutic antibodies, earning royalties on licensed drug candidates.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $ABCL.

Biotechnology · Healthcare

GLP-1 oral formulation competition — emerging clinical data from pipeline challengers — is the central bifurcation: platform holders (LLY, NVO) defend on efficacy breadth while precision oncology names decouple entirely. FDA catalyst cadence over the next 60 days sets the near-term tone.

What this means for $ABCL

Partial — branded pharmaceutical revenue is exposed to patent cliff dynamics and GLP-1 category cannibalization; AbCellera Biologics Inc.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+48.9%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-11.8How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-13.8%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-268%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-11.0%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
21.7Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-14.9%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
79.1%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 5, 2026$-0.18$-0.16-9.8%
Q1 2026May 11, 2026$-0.14$-0.22+36.4%
Q4 2025Feb 24, 2026$-0.03$-0.18+83.3%
Q3 2025Nov 6, 2025$-0.19$-0.17-11.8%
Next earningsThu, Nov 5·consensus EPS $-0.18

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$8.3M+96.3%-4.1%-692%$-0.14$-37.4M
Q4 FY25$44.9M+788.2%82.3%-63.7%$-0.03$-44.6M
Q3 FY25$9.0M+37.6%100%-852%$-0.19$-61.5M
Q2 FY25$17.1M+133.3%100%-290%$-0.12$-45.8M

Forward consensus

5-year forecast · up to 7 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$32.0M$27.0M – $40.4M-$0.59-$0.60 – -$0.577
FY27$30.9M$7.4M – $47.9M-$0.64-$0.68 – -$0.626
FY28$33.2M$5.3M – $51.9M-$0.82-$0.97 – -$0.674
FY29$63.7M$29.9M – $91.9M-$0.76-$1.20 – -$0.243
FY30$124.0M$58.2M – $178.8M-$0.65-$1.02 – -$0.203

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.6×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.89%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+43.8%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+130.4%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatHigh float · 205.1M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today2.4% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.195-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Cluster buy3 insiders bought shares in the last 30 days.

Recent transactions

BuyAug 24Michael R HaydenDirector53.6K sh$570KBuyAug 18John S. MontalbanoDirector10.0K sh$110KBuyAug 14Andrew BoothCFO37.2K sh$384KBuyAug 12Michael R HaydenDirector46.4K sh$481KBuyMay 14John S. MontalbanoDirector20.0K sh$95K
+ 6 other (5 awards · 1 gift) in window

See when $ABCL insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KMaterial agreementAug 138-K — Item 1.01: Material agreement · Item 8.01: Other event
AI summary

AbCellera Biologics (ABCL) filed an 8-K on August 13, 2026 (event date August 12) under Items 1.01 and 8.01, announcing a material definitive agreement alongside other events. The excerpt is the cover page; the specific agreement details are in the body. This 8-K was filed concurrently with AbCellera's prospectus supplement (424B5) for a share offering, suggesting the agreement may be related to the capital raise — potentially a licensing deal, collaboration, or stock purchase agreement with a counterparty. AbCellera is a clinical-stage antibody discovery company.

424B5Prospectus supplement (offering)Aug 13424B5
AI summary

AbCellera Biologics (ABCL) filed a 424B5 prospectus supplement on August 13, 2026, pricing an equity offering of 17,435,897 shares of common stock plus 3,076,926 pre-funded warrants, with the last reported sale price cited as $10.36 per share. The total gross proceeds would be approximately $211M at that price, representing meaningful dilution for existing shareholders. The offering was filed the same day as AbCellera's 8-K announcing a material agreement, suggesting proceeds may be tied to a strategic transaction or clinical program funding. AbCellera is a clinical-stage antibody discovery and development company.

424B5Prospectus supplement (offering)Aug 11424B5
AI summary

AbCellera Biologics (ABCL) is conducting a preliminary $200 million equity offering consisting of common shares and, for investors preferring not to hold shares immediately, pre-funded warrants exercisable at $0.00001 per share. This is a preliminary (subject to completion) prospectus supplement filed August 11, 2026; pricing has not yet been set. The last reported sale price on Nasdaq on August 10, 2026 was $9.32 per share. AbCellera is a Canadian company listed on Nasdaq, and investors are purchasing interests in a Canadian entity.

8-KPress release / Reg FDAug 108-K — Item 7.01: Press release / Reg FD
AI summary

AbCellera Biologics Inc. (ABCL) filed a Reg FD disclosure (Item 7.01) on 2026-08-10, furnishing conference call and webcast at 4:30 a. Reg FD filings ensure simultaneous public disclosure of material information shared with select investors. This is generally an informational filing; no new deal terms or financial results were announced unless noted. Investors should review the attached exhibit for updated guidance or strategic commentary.

8-KPress release / Reg FDAug 58-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
AI summary

ABCL reported financial results for quarter. Full results are disclosed in a press release filed as Exhibit 99.1. Item 2.02 mandates simultaneous disclosure of material earnings data, ensuring all investors receive results at the same time. Investors should review the attached exhibit for complete financial figures and any forward guidance from ABCL management.

3New insider — initial holdingsJul 63
AI summary

Lynn Seely filed an initial Form 3 as a newly appointed director of AbCellera Biologics Inc. (ABCL), effective June 30, 2026, disclosing no securities beneficially owned. This is a mandatory administrative filing upon becoming a Section 16 reporting person — no ownership stake or economic exposure to report.

8-KOfficer or director changeJul 68-K — Item 5.02: Officer or director change
AI summary

AbCellera Biologics Inc. appointed Lynn Seely, M.D. as a new Class III director effective June 30, 2026, to serve until the 2029 annual meeting of shareholders or until her earlier resignation or removal. The Board determined Dr. Seely is independent under Nasdaq rules and she will participate in the company's standard Non-Employee Director Compensation Policy on the same terms as other non-employee directors. No committee assignments were made at this time, and she has no material related-party transactions with the company. This is a routine governance appointment — adding an independent director to the ABCL board with no significant strategic or financial implications beyond normal board compensation.

8-KShareholder voteJun 128-K — Item 5.07: Shareholder vote
AI summary

AbCellera Biologics Inc. held its 2026 Annual Meeting of Shareholders on June 11, 2026, with 305,264,947 shares eligible to vote. Shareholders elected Class III directors John S. Montalbano and Stephen R. Quake to three-year terms; ratified Ernst & Young LLP as auditor; and approved Say-on-Pay on a non-binding advisory basis — all three proposals passed. Routine annual governance vote with no contested proposals or material changes to compensation structure.

+ 12 other (3 routine 8-Ks · 2 10-Qs · 2 8-Ks · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

What'sGoing On With AbCellera Biologics Stock On Tuesday?benzinga.com·7d agoAre Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yesseekingalpha.com·15d agoAbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrantsbusinesswire.com·19d agoWhat's Going on With AbCellera Biologics Stock On Wednesday?benzinga.com·20d agoAbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrantsbusinesswire.com·21d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALT$AURA$IOVA$NWBO$SLS$AMLX$ABVX
Voices on X · top 15 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport